CCNB2, TOP2A, and ASPM Reflect the Prognosis of Hepatocellular Carcinoma, as Determined by Weighted Gene Coexpression Network Analysis

Table 1

Associations between CCNB2, TOP2A, and ASPM expressions and clinicopathological features.

Variables		CCNB2				TOP2A				ASPM
		Low ()	High ()		P	Low ()	High ()			Low ()	High ()
Age (years)	<50	29	39	1.41	0.24	30	38	0.84	0.36	31	37	0.42	0.52
	≥50	152	143			151	144			150	145
Gender	Female	51	67	2.70	0.10	50	68	3.49	0.06	54	64	0.95	0.33
	Male	130	115			131	114			127	118
Race	Asian	65	90	6.26	0.01	63	92	8.56	0.003	66	89	5.24	0.02
	Non-Asian	116	92			118	90			115	93
New tumor events	No	108	91	3.05	0.08	104	95	0.81	0.37	110	89	4.70	0.03
	Yes	73	91			77	87			71	93
Tumor stage	I-II	149	129	6.00	0.01	147	131	3.82	0.05	146	132	2.91	0.09
	III-IV	32	53			34	51			35	50
Fetoprotein (ng/ml)	<500	125	91	17.07	<0.001	121	95	10.19	0.001	119	97	9.39	0.002
	≥500	16	44			19	41			19	41